Land: Israel
Språk: engelsk
Kilde: Ministry of Health
ACLIDINIUM AS BROMIDE; FORMOTEROL FUMARATE DIHYDRATE
ASTRAZENECA (ISRAEL) LTD
R03BB05
POWDER FOR INHALATION
FORMOTEROL FUMARATE DIHYDRATE 11.8 MCG; ACLIDINIUM AS BROMIDE 340 MCG
INHALATION
Required
INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A., SPAIN
ACLIDINIUM BROMIDE
Maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD)
2021-01-31
Patient Package Leaflet in Accordance With the Pharmacists’ Regulations (Preparations) – 1986 The medicine is dispensed with a doctor’s prescription only Duaklir® Genuair® 340/12 micrograms inhalation powder Active ingredients: Each dose for inhalation contains: 396 mcg aclidinium bromide, equivalent to 340 mcg aclidinium and 11.8 mcg formoterol fumarate dihydrate. For a list of inactive ingredients please refer to Section 6. See also ‘Important information about some of the ingredients of the medicine’ in Section 2. Read this leaflet carefully in its entirety before using the medicine. Keep this leaflet, you may need it again. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. This medicine has been prescribed for the treatment of your ailment. Do not pass it on to others. It may harm them, even if it seems to you that their ailment is similar. This medicine is not intended for children and adolescents under the age of 18 years. 1. WHAT IS THE MEDICINE INTENDED FOR? This medicine is used as maintenance bronchodilator treatment in order to relieve symptoms in adults who suffer from COPD (chronic obstructive pulmonary disease). In this disease the airways in the lungs become damaged or blocked. By opening the airways, the medicine helps relieve symptoms such as shortness of breath. Using the inhaler regularly will help to minimise the effects of COPD on your everyday life. Therapeutic group: This medicine contains two active ingredients from the bronchodilators group. Aclidinium bromide: anticholinergic. Formoterol fumarate dihydrate: beta-agonist (long lasting activity). 2. BEFORE USING THE MEDICINE Do not use the medicine if: Special warnings regarding use of the medicine: Before treatment with Duaklir Genuair, tell the doctor if you have: • asthma. This medicine should not be used for the treatment of asthma • heart problems • epilepsy • thyroid gland problems (thyrotoxicosis) • a tumour in one of your adrenal gla read_full_document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Duaklir Genuair 340 micrograms /12 micrograms inhalation powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose leaving the mouthpiece) contains 396 micrograms of aclidinium bromide (equivalent to 340 micrograms of aclidinium) and 11.8 micrograms of formoterol fumarate dihydrate. This corresponds to a metered dose of 400 micrograms of aclidinium bromide (equivalent to 343 micrograms of aclidinium) and a metered dose of 12 micrograms of formoterol fumarate dihydrate. Excipients with known effect: Each delivered dose contains approximately 11 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Inhalation powder. White or almost white powder in a white inhaler with an integral dose indicator and an orange dosage button. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Duaklir Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is one inhalation of Duaklir Genuair 340 micrograms /12 micrograms twice daily. If a dose is missed, it should be taken as soon as possible and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose. Elderly No dose adjustments are required in elderly patients (see section 5.2). Renal impairment No dose adjustments are required in patients with renal impairment (see section 5.2). Hepatic impairment No dose adjustments are required in patients with hepatic impairment (see section 5.2). Paediatric population There is no relevant use of Duaklir Genuair in children and adolescents (under 18 years of age) for the indication of COPD. Method of administration For inhalation use. Patients should be instructed on how to administer the product correctly as the Genuair inhaler may work differently from inhalers the patients may have read_full_document